We read the interesting article ‘The truth about artificial sweeteners – are they good for diabetes’ by Purohit and Mishra published in your esteemed journal. This paper brings out clearly and convincingly side effects associated with currently popular sweeteners namely saccharin, aspartame, neotame and sucralose particularly their cancer producing potentials. On the other hand, there is a brief mention about stevia which is derived from plant *Stevia rebaudiana*. It possesses unique property of not only having a sweet taste but also sugar lowering and lipid lowering property – a distinct advantage over chemical sweeteners. Stevia *rebaudiana* contains steviol glycosides namely steviosides, rebaudioside, steviolbioside and isosteviol, which are responsible for its sweetness and sugar lowering properties. It has been said to be safe in long term use. Interestingly while stevia is a safe sweetener the currently popular chemical sweeteners have potential to cause cancer when used for long time. It is also well known that these sweeteners are used in many smokeless tobacco products like *gutkha* and *paan masala* preparations and these patients are reported to have oral and bladder carcinoma. Further looking at the current pandemic of diabetes prevailing all over Indian subcontinent, use of stevia as an alternative sweetening agent for people who have diabetes, pre-diabetes and/or obesity needs to be explored in robust statistically designed studies.

**Conflicts of interest of each author**

None.

**References**

1. Lyon AR, Bossone E, Schneider B, et al. Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2016;18:8–27.
2. Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo syndrome. Circulation. 2017;135:2426–2441.
3. Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. *Nat Clin Pract Cardiovasc Med*. 2008;5:22–28.
4. Gupta S, Gupta MM. Takotsubo syndrome. *Indian Heart J*. 2018;70:165–174.
5. Pelliccia F, Sinarig G, Elliott P, Parodi G, Basso C, Camici PG. Takotsubo is not a cardiomyopathy. *Int J Cardiol*. 2018;254:250–253.
6. Doehner W, Ural D, Haersuler KG, et al. Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. *Eur J Heart Fail*. 2018;20:199–215.
7. Madias JE. Coronary vasospasm is an unlikely cause of Takotsubo syndrome, although we should keep an open mind. *Int J Cardiol*. 2014;176:1–5.
8. Alfonso CE. Takotsubo cardiomyopathy and coronary artery disease: a meaningful coincidence? *J Am Heart Assoc*. 2016;5.
9. Hung MJ, Ko T, Liang CY, Kao YC. Two-dimensional myocardial deformation in coronary vasospasm-related Takotsubo cardiomyopathy: a case report of a serial echocardiographic study. *Medicine (Baltimore)*. 2017;96:e8232.
10. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013;34:2949–3003.
11. Silva MP, Vilela EM, Lopes RI, et al. Cardiogenic shock induced by Takotsubo cardiomyopathy: a new therapeutic option. *Rev Port Cardiol*. 2015;34(695):e1–e4.

Eduardo Vilela*  
Marisa Silva  
Cláudio Guerreiro  
Daniel Caetano  
Marlene Fonseca  
João Primo  
Pedro Braga  
Vasco Gama  
Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre  
Rua Conceição Fernandes, 4434-502, Vila Nova de Gaia, Portugal  
* Corresponding author.  
E-mail address: eduardomvilela@gmail.com (E. Vilela).

Received 4 April 2018  
Available online 10 April 2018

http://dx.doi.org/10.1016/j.ihj.2018.04.004

Stevia *rebaudiana* the unique medicinal plant with sweet taste having hypoglycemic and hypolipidemic activities

The Editor,
Authors reply: Stevia: Long term data is lacking!

Reply

We agree with the letter that Stevia may be the safest among the currently available artificial sweeteners, however there are some limitations to this product as well. They are more expensive than natural “sugar,” have some minor side effects (bloating, nausea, etc.) but most importantly have licorice flavor and somewhat bitter after-taste so much so that they are not liked by most. Interestingly, while Food and Drug Administration, USA has approved refined Stevia (product Rebaudioside A) as generally recognized as safe (GRAS), it has not approved leaf or extract of Stevia as GRAS because of possible effect on reproductive, renal or cardiovascular system. In any case robust, long term (5 years or so) data on clinical outcomes with Stevia is still lacking.

Vikas Purohit
Sundeep Mishra *
Department of Cardiology, AIIMS, India

* Corresponding author.
E-mail address: sundeepmishrai@ihj@gmail.com (S. Mishra).

Received undefined

http://dx.doi.org/10.1016/j.ihj.2018.06.012

Exercise based evaluations and rehabilitation in heart failure: An addendum to the Cardiology Society of India's management protocols for chronic heart failure

The Editor,

We read with great interest the comprehensive consensus document on management of chronic heart failure (HF) recently published in the Indian Heart Journal.1 To elaborate on the rehabilitative aspect, we hereby propose a rehabilitation algorithm for both hospitalized and out-patient, stable HF patients.

Exercise-based evaluations

Evaluation of exercise capacity is a crucial step to the functional assessment of patients with HF. Though the gold standard remains to be cardiopulmonary exercise testing, high costs of establishing labs makes this option unviable in India. Therefore, the use of the six minute walk test to assess the distance covered (6MWD). The test is safe and can be used across all classes of HF. Clinical monitoring using the 6MWD is useful and can be easily done with no extra costs of infrastructure.

Rehabilitation of HF

Participation in exercise training and physical activity for HF is a class I, Level A recommendation.2 Recently, there has been a focus on early rehabilitation of acute HF patients. A previous study from our center found that participation in early CR for acute HF improved discharge 6MWD as compared to those not receiving early CR.3 Discharge evaluations with the 6MWD is important as it would guide exercise prescription following discharge.

Phase-2 CR requires patients to continue exercise either under supervision in a center or at home. With the barriers to CR in the Indian context highlighted in previous studies,4 supervised programs may not always be feasible. Thus, the need for low intensity home based programs which can be administered by an CR exercise specialist to ensure safety. Based on our data and current clinical practice, and on the early CR algorithm proposed for ST elevation myocardial infarction5 we propose a clinical rehabilitation algorithm for HF patients for both early and subsequent phase-2 CR (Fig. 1a and b).